Evidence‑Based Management of Pan‑Resistant Klebsiella pneumoniae Bacteremia

Therapeutic Recommendations

The International Journal of Antimicrobial Agents recommends ceftazidime/avibactam or meropenem/vaborbactam as first-line treatments for KPC-producing K. pneumoniae infections, with a strong recommendation and moderate certainty of evidence 2
Ceftazidime/avibactam or meropenem/vaborbactam are strongly recommended as first-line treatments for KPC-producing K. pneumoniae infections (STRONG recommendation, MODERATE certainty of evidence) 2
Meropenem/vaborbactam monotherapy showed higher clinical cure rates, decreased mortality, and reduced nephrotoxicity compared to best available therapy in the TANGO II study 2

Imipenem/relebactam and cefiderocol may be considered as alternatives for KPC-producing K. pneumoniae (CONDITIONAL recommendation, LOW certainty of evidence) 2
Fosfomycin-containing combination therapy may be considered, particularly in combination with tigecycline, polymyxin, or carbapenems 3

Meropenem/vaborbactam may be preferred for respiratory infections (pneumonia) due to better epithelial lining fluid concentrations (intrapulmonary penetration ratios of 63% for meropenem and 65% for vaborbactam) 2

Therapeutic drug monitoring (TDM) should be considered for critically ill patients, especially when using polymyxins or aminoglycosides 3
Dose adjustments are necessary for most antimicrobial agents in patients with renal dysfunction 3

Monitor for emergence of resistance, particularly with ceftazidime/avibactam (resistance rates range from 0% to 12.8%) 2

KPC variants (e.g., mutations in the blaKPC-3 gene, D179Y variants) can confer resistance to ceftazidime/avibactam; in such cases, meropenem/vaborbactam may be a therapeutic option 2

For uncomplicated bacteremia, a minimum of 7-14 days of appropriate therapy is recommended 4